Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost

MM El Tabaa, MM El Tabaa - Biochemical Pharmacology, 2020 - Elsevier
COVID-19 is an ongoing viral pandemic disease that is caused by SARS-CoV2, inducing
severe pneumonia in humans. However, several classes of repurposed drugs have been …

Protective renal effects of atrial natriuretic peptide: where are we now?

MR Choi, BE Fernández - Frontiers in Physiology, 2021 - frontiersin.org
Atrial natriuretic peptide belongs to the family of natriuretic peptides, a system with
natriuretic, diuretic, and vasodilator effects that opposes to renin-angiotensin system. In …

Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats

Q Li, Y Fang, D Peng, L Li, C Deng, H Yang… - European Journal of …, 2023 - Elsevier
Abstract Aim Sacubitril/valsartan (Sac/Val, LCZ696), the world's first angiotensin receptor-
neprilysin inhibitor (ARNi), has been widely used in the treatment of heart failure. However …

The angiotensin receptor neprilysin inhibitor LCZ696 attenuates renal fibrosis via ASK1/JNK/p38 MAPK-mediated apoptosis in unilateral ureteral obstruction

J Ding, S Cui, SY Li, LY Cui, QY Nan, XJ Lin, MY Xuan… - Plos one, 2023 - journals.plos.org
The angiotensin receptor neprilysin inhibitor LCZ696 affords superior cardioprotection and
renoprotection compared with renin-angiotensin blockade monotherapy, but the underlying …

Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF

KS Jering, F Zannad, B Claggett, FR Mc Causland… - Heart Failure, 2021 - jacc.org
Objectives This study sought to evaluate the efficacy and safety of sacubitril/valsartan in
patients with heart failure with preserved ejection fraction (HFpEF) according to background …

[HTML][HTML] Potential effects and application prospect of angiotensin receptor-neprilysin inhibitor in diabetic kidney disease

X Zhang, Y Zhou, R Ma - Journal of Diabetes and its Complications, 2022 - Elsevier
Diabetic kidney disease (DKD) is one of the main causes of end-stage renal disease
(ESRD) and all-cause mortality in diabetic patients, despite the extensive use of angiotensin …

Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in db/db mice and KKAy mice compared with valsartan treatment

K Myakala, BA Jones, XX Wang… - American Journal of …, 2021 - journals.physiology.org
Although renin-angiotensin blockade has shown beneficial outcomes in patients with
diabetes, renal injury progresses in most of these patients. Therefore, there remains a need …

Renoprotective effects of small interfering RNA targeting liver angiotensinogen in experimental chronic kidney disease

DM Bovée, L Ren, E Uijl… - …, 2021 - Am Heart Assoc
Small interfering RNA (siRNA) targeting liver angiotensinogen (AGT) lowers blood pressure,
but its effectiveness in hypertensive chronic kidney disease is unknown. Considering that …

Potential of renin-angiotensin-aldosterone system modulations in diabetic kidney disease: old players to new hope!

V Malek, SV Suryavanshi, N Sharma… - Reviews of physiology …, 2021 - Springer
Due to a tragic increase in the incidences of diabetes globally, diabetic kidney disease
(DKD) has emerged as one of the leading causes of end-stage renal diseases (ESRD) …

Blood pressure‐independent renoprotective effects of small interference RNA targeting liver angiotensinogen in experimental diabetes

EO Cruz‐López, L Ren, E Uijl… - British Journal of …, 2023 - Wiley Online Library
Background and Purpose Small interfering RNA (siRNA) targeting liver angiotensinogen
lowers blood pressure, but its effects in hypertensive diabetes are unknown. Experimental …